Israel - English - Ministry of Health

medison pharma ltd - odevixibat as sesquihydrate - hard capsule - odevixibat as sesquihydrate 400 mcg - odevixibat - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or olderbylvay is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with alagille syndrome (algs).

Israel - English - Ministry of Health

medison pharma ltd - odevixibat as sesquihydrate - hard capsule - odevixibat as sesquihydrate 600 mcg - odevixibat - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or olderbylvay is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with alagille syndrome (algs).

Israel - English - Ministry of Health

medison pharma ltd - mogamulizumab - concentrate for solution for infusion - mogamulizumab 4 mg / 1 ml - mogamulizumab - poteligeo is indicated for the treatment of adult patients with mycosis fungoides (mf) or sézary syndrome (ss) who have received at least one prior systemic therapy.

Israel - English - Ministry of Health

medison pharma ltd - carglumic acid - tablets dispersible - carglumic acid 200 mg - carglumic acid - carglumic acid - carbaglu is indicated in treatment of :- hyperammonaemia due to n - acetylglutamate synthase primary deficiency.- hyperammonaemia due to isovaleric acidaemia.- hyperammonaemia due to methymalonic acidaemia.- hyperammonaemia due to propionic acidaemia.

Israel - English - Ministry of Health

medison pharma ltd - galsulfase - concentrate for solution for infusion - galsulfase 1 mg/ml - galsulfase - galsulfase - naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mpsvi (n-acetylglactosamine 4 sulfatase deficiency maroteaux-lamy syndrome).

Israel - English - Ministry of Health

medison pharma ltd - bezafibrate - tablets sustained release - bezafibrate 400 mg - bezafibrate - bezafibrate - hyperlipidemia of types iia, iib, iii, iv, v in patients where diet alone is insufficient.

Israel - English - Ministry of Health

medison pharma ltd - doxorubicin hydrochloride - powder,dispersion and solvent for concentrate for dispersion for infusion - doxorubicin hydrochloride 50 mg vials - doxorubicin - doxorubicin - myocet, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in women.

Israel - English - Ministry of Health

medison pharma ltd - arsenic trioxide - solution for injection - arsenic trioxide 1 mg/ml - arsenic trioxide - arsenic trioxide - trisenox is indicated for induction of remission, and consolidation in adult patients with:• newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 1000/μl) in combination with all-trans-retinoic acid (atra)• relapsed/refractory acute promyelocytic leukaemia (apl)(previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rar-alpha) gene.the response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.

Israel - English - Ministry of Health

medison pharma ltd - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.

Israel - English - Ministry of Health

medison pharma ltd - ponatinib as hydrochloride - coated tablets - ponatinib as hydrochloride 15 mg - ponatinib - iclusig is indicated in adult patients with: • chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation • philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation.